Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Smith & Nephew    SN.   GB0009223206

SMITH & NEPHEW (SN.)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/15/2018 10/16/2018 10/17/2018 10/18/2018 10/19/2018 Date
1281(c) 1280(c) 1266.5(c) 1274.5(c) 1282 Last
2 910 993 4 006 599 3 539 964 2 696 038 808 697 Volume
-1.12% -0.08% -1.05% +0.63% +0.59% Change
More quotes
Financials (USD)
Sales 2018 4 947 M
EBIT 2018 1 018 M
Net income 2018 655 M
Debt 2018 1 049 M
Yield 2018 2,10%
Sales 2019 5 101 M
EBIT 2019 1 096 M
Net income 2019 765 M
Debt 2019 753 M
Yield 2019 2,38%
P/E ratio 2018 22,01
P/E ratio 2019 18,90
EV / Sales2018 3,17x
EV / Sales2019 3,01x
Capitalization 14 614 M
More Financials
Company
Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices.It offers the following products and services: sports medicine joint repair; arthroscopic enabling technologies; trauma and extremities; other surgical businesses; knee and hip implants, and advanced... 
More about the company
Surperformance© ratings of Smith & Nephew
Trading Rating : Investor Rating :
More Ratings
Latest news on SMITH & NEPHEW
10/18SMITH & NEPHEW : Two new studies demonstrate INTERTAN Intertrochanteric Antegrad..
AQ
10/18SMITH & NEPHEW : Dividend Declaration
PU
10/17SMITH & NEPHEW : Two new studies demonstrate INTERTAN™ Intertrochanteric A..
PU
10/17SMITH & NEPHEW : Timing of Smith & Nephew third quarter trading report
PU
10/17SMITH & NEPHEW : Notice of Results
PU
10/16SMITH & NEPHEW : launches PICO™ 7Y, the first portable single use negative..
PU
10/11SPORTS MEDICINE MARKET IS ANTICIPATE : Knee and Hip Applications Accounted for H..
AQ
10/04SMITH & NEPHEW : Ex-dividend day for interim dividend
FA
10/01SMITH & NEPHEW : Notice of Results
PU
09/25SMITH & NEPHEW : Excelera Specialty Pharmacy Network Announces Partnership with ..
AQ
More news
Sector news : Medical Devices & Implants
10/17Health Care Up On Stronger Earnings -- Health Care Roundup
DJ
10/17ABBOTT LABORATORIES : Meets Expectations in Latest Quarter, Narrows Outlook
DJ
10/16STRATEGY : Has being defensive paid off since the 2008 crisis?
10/16ABBVIE : The Strategies AbbVie Employed to Protect Humira From Copycats
DJ
10/15ABBOTT LABORATORIES : Names Robert B. Ford President, Chief Operating Officer
DJ
More sector news : Medical Devices & Implants
MarketScreener Strategies on SMITH & NEPHEW 
SMITH & NEPHEW  - 2015
Near a major level
SELL
SMITH & NEPHEW PLC - 2013
Lower limit of a trading channel
BUY
More Strategies
Latest Tweets
09/28$SN. Nephew PLC Smith Nephew - Turning over that new leaf: We had the opport.. 
06/14WPP chairman Roberto Quarta should follow Sir Martin Sorrell out the door  
06/13WPP chairman Roberto Quarta should follow Sir Martin Sorrell out the door  
06/12WPP chairman Roberto Quarta should follow Sir Martin Sorrell out the door
2
06/11Revealed: WPP chairman Roberto Quarta will suffer a more limited revolt, with.. 
More tweets
Qtime:98
News from SeekingAlpha
10/08Medical device makers in the red 
10/03Smith & Nephew goes ex-dividend tomorrow 
07/30Netflix re-releases documentary critical of medical device industry 
07/27Stryker's Exceptional Growth Supports A Gravity-Defying Valuation 
07/26Smith & Nephew Plc (SNN) CEO Namal Nawana on Q2 2018 Results - Earnings Call .. 
Chart SMITH & NEPHEW
Duration : Period :
Smith & Nephew Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SMITH & NEPHEW
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 18,3 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Namal Nawana Chief Executive Officer & Executive Director
Roberto Quarta Chairman
Mark Gladwell President-Global Operations
Graham James Baker Chief Financial Officer & Director
Vasant Padmanabhan President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SMITH & NEPHEW-0.54%14 614
STRYKER CORPORATION10.46%64 738
WRIGHT MEDICAL GROUP NV21.89%3 533
GLAUKOS CORP133.18%2 197
JAPAN LIFELINE CO., LTD.-10.36%1 693
DOUBLE MEDICAL TECHNOLOGY INC--.--%1 499